PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Virus-Immunotherapy combo targets Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a specially modified virus (VSV-hIFNβ-NIS) combined with two immunotherapy drugs (ipilimumab and cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells without harming healthy ones, while the immu…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 08:34 UTC
-
New hope for tough lymphoma: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard single-agent treatments in 150 adults with certain types of T-cell lymphoma that have come back or not responded to prior therapy. The goal is to see if soquelitinib can delay cancer progression better than current …
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:30 UTC
-
New drug Q702 aims to boost immune system against Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, Q702, in about 46 adults with certain blood cancers or related diseases that have not responded to standard treatments. Q702 works by helping the immune system attack cancer cells and supporting normal blood cell production. The main goals…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Could a stem cell transplant keep T-Cell lymphoma away longer?
Disease control Recruiting nowThis study compares two approaches for adults with peripheral T-cell lymphoma who are in complete remission after initial chemotherapy: either a high-dose chemotherapy followed by a transplant of their own stem cells, or simply watching and waiting. The goal is to see if the tran…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Massive T-Cell lymphoma database aims to unlock better treatments
Knowledge-focused Recruiting nowThis study is creating a large database of information from 1,000 people with T-cell lymphoma. Researchers will collect medical records and tumor samples to learn more about the disease and how to improve care. No new treatments are being tested; the goal is to gather data for fu…
Matched conditions: PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC